CFP NOSTAGAIN and IMNN joint event: CFP: SPRING INTO NOSTALGIA – PLONGER DANS LA NOSTALGIE What does nostalgia ‘look’ and feel like in your everyday life as researchers, artists, media c…

Reported Thursday, Sep 24 - 8:19am EDT (TheFly subscription required to read more.)

An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.

YouTube video by MEZERG

YouTube video by MEZERG

Reported Tuesday, Sep 22 - 8:27am EDT (TheFly subscription required to read more.)

The film District 9 made waves as an allegory of apartheid on the big screen, but it has not yet been given its rightful place as a landmark depiction within broader visual cultural studies of…

Click to view the official SEC document.

YouTube video by 7Seconds - Topic

Provided to YouTube by The Orchard EnterprisesWalk Together, Rock Together · 7Seconds · Better Youth Organization, PRO: ASCAP, IPI: 127316493Walk Together, R...

Stacy Lindborg, PhD, highlights the vaccine’s immune response, safety, and global distribution potential.

IMUNON (NASDAQ: IMNN) has announced new translational data from its Phase 1/2 OVATION 2 Study of IMNN-001 in advanced ovarian cancer. The study demonstrated a 20% increase in IL-12 levels with the 100mg/m2 dose compared to the 79mg/m2 dose when administered with standard-of-care chemotherapy.The data showed increased levels of anti-cancer immune cytokines IFN-γ and TNF-α in the tumor microenvironment, with minimal systemic impact. The treatment maintained a favorable safety profile with no serious immune-related adverse events. Previous December 2024 results showed a 13-month improvement in median overall survival with IMNN-001 plus standard care versus standard care alone. More than one-third of patients survived beyond 36 months, with 62% from the IMNN-001 treatment arm.Following an End-of-Phase 2 FDA meeting, IMUNON is proceeding with a Phase 3 pivotal trial in Q1 2025.